Judge Invalidates Bristol-Myers Patent For Hepatitis B Drug
A Delaware federal judge on Monday struck down a Bristol-Myers Squibb Co. patent on the hepatitis B drug Baraclude as obvious, a ruling in favor of generic drugmaker Teva Pharmaceutical Industries...To view the full article, register now.
Already a subscriber? Click here to view full article